Shi-Tao Wang

Identification of Four Compounds with S-RBD-Binding and Pseudovirus Entry-Inhibitory Activity

COVID-19, caused by SARS-CoV-2, remains a global health challenge because of viral evolution and immune escape. Although current therapies primarily target viral entry and replication, agents that directly interfere with the Spike receptor-binding domain (S-RBD) remain limited. Here, we combined virtual screening with...